Raynaud's Phenomenon

Rheum Dis Clin North Am. 1996 Nov;22(4):765-81. doi: 10.1016/s0889-857x(05)70300-8.

Abstract

Raynaud's phenomenon is a common clinical problem occurring in 3% to 5% of the general population. The first symptom of scleroderma is often Raynaud's phenomenon, which is associated with a diffuse small vessel vasculopathy and ischemia and reperfusion injury to skin and other organs targeted in this disease. Current studies support the concept that Raynaud's phenomenon is secondary to a local defect in the regulation of regional blood flow. New evidence demonstrates that there is a profound sensitivity to alpha 2-adrenoceptors mediated vasoconstriction in scleroderma vessels. Traditional treatment of Raynaud's phenomenon is cold avoidance and the use of vasodilators. Oral prostaglandins have shown promise as therapeutic agents.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Humans
  • Microcirculation
  • Prostaglandins / therapeutic use
  • Raynaud Disease / diagnosis
  • Raynaud Disease / physiopathology*
  • Raynaud Disease / therapy
  • Scleroderma, Systemic / diagnosis
  • Scleroderma, Systemic / physiopathology*
  • Scleroderma, Systemic / therapy

Substances

  • Prostaglandins